ArticlePloS one2025
Molecular docking and MD simulations predicted quercetin as a potent human interleukin-1 beta (hIL1β) inhibitor for improved endodontic disease management.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Protective Effects of Virgin Olive Oil Against Titanium Dioxide Nanoparticle-Induced Hepato-Renal Toxicity: Evidence from Oxidative Stress Biomarkers and Restoration of Antioxidant Enzyme Activities.Biological trace element research · 2026Article
- Article
- In Silico and In Vitro Evaluation of Quercetin Metabolites Binding to Inflammatory Target Proteins.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Comparative Metabolomics and Network Pharmacology Study Reveals Chemopreventive Potential of Wild Soybean (Foods (Basel, Switzerland) · 2026Article
- The identification of metabolites from gut microbiota in HPV infection via network pharmacology.PloS one · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
IL1β, a pro-inflammatory cytokine, is a key mediator in the inflammatory processes linked to endodontic disorders. Studies have shown that IL1β production is elevated in symptomatic periapical lesions, highlighting its involvement in inflammation and lesion development. Elevated levels of IL1β correlate with larger lesion sizes and increased inflammation in periapical tissues. Given its role in inflammation, IL1β represents a potential therapeutic target for endodontic diseases, including the use of IL1β inhibitors. The present study used molecular docking and MD simulations to identify small molecule inhibitors of hIL1β. A small library of 329 plant-derived natural compounds was screened against hIL1β, the top five hits were selected based on their binding affinity and score and docked with hIL1β. Molecular docking results showed that Quercetin has the highest binding affinity (-10.3 kcal/mol) and exibits favorable interactions with hIL1β compared to the other four hits. Based on these observations, Quercetin was further subjected to MD simulations with hIL1β. MD trajectories were used to determine the interaction and stability of the hIL1β-Quercetin complex using various parameters, such as RMSD, RMSF, Rg, SASA, and hydrogen bond count of the apo hIL1β and Quercetin-hIL1β complex. Consistent RMSD, RMSF, Rg, and SASA values indicated the stability of the complex. Furthermore, hydrogen bond count emphasized the Quercetin's role as a non-disruptive binder. Moreover, secondary structure analysis, PCA, and calculations of Gibbs free energy revealed minimal structural changes and highlighted the stable conformational state of hIL1β upon Quercetin binding, suggesting a stabilizing effect of Quercetin. These observations suggest Quercetin's potential in the development of new treatments for endodontic diseases, which may lead to improved clinical outcomes and reduced recurrence rates.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.